PharmaFocus Today – Page 64 – media

Innovation-Driven Vaccine Upgrades, Focusing on Core Products and Pipeline Development

After fifteen years of deep cultivation in the vaccine field, AB&B Bio Tech has accelerated on the path of differentiated innovation. Listed on the Hong Kong Stock Exchange in August, AB&B Bio Tech has fortified its competitive edge with core products such as its first quadrivalent subunit influenza vaccine covering all age groups from 6 months and above. Its Hong Kong IPO was oversubscribed by over 4,000 times. In a recent exclusive interview with China Securities Journal, An Youcai, Chairman and General Manager of AB&B Bio Tech, comprehensively detailed the company’s product strategy, performance delivery logic, use of raised funds, and future development blueprint. He clarified that with “innovation-driven” as the core, the company aims to achieve a revenue target of RMB 2 billion by 2030 through capacity expansion and international布局, striving to join the top tier of domestic vaccine enterprises. Differentiated Strategy Enhances Product Competitiveness AB&B Bio Tech listed ...
- Source: drugdu
- 138
- December 16, 2025
Huadong Medicine has made a significant leap in international research and development. Its new product has been granted orphan drug status by the FDA

On December 15th, Huadong Medicinel (000963) announced that its independently developed ADC innovative drug, Injection HDM2012, has obtained orphan drug qualification recognition (Orphan Drug Designation, ODD) from the US Food and Drug Administration (referred to as “US FDA”) for two indications: gastric cancer and gastroesophageal junction cancer, as well as pancreatic cancer. This proves that the innovative nature of its ADC research has been internationally recognized. Meanwhile, the innovative multi-peptide-based long-acting agonist HDM1005 injection for dual-targeting human GLP-1 (glucagon-like peptide-1) receptor and GIP receptor (glucose-dependent insulinotropic polypeptide), developed by the wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “Zhongmei Huadong”), achieved positive results in the Phase II clinical trial for weight management indications in China. These two milestones signify a significant leap forward for Huadong Pharmaceutical in the internationalization and cutting-edge exploration of new drug research. They not only demonstrate the company’s successful implementation of its ...
- Source: drugdu
- 159
- December 16, 2025
Rona Therapeutics Completes First Cohort Dosing in First-in-Human Phase 1 Clinical Trial of Obesity Treatment RN3161

Rona Therapeutics announced on December 15, 2025, that Cohort 1 dosing for their RN3161 drug, a GalNAc-conjugated siRNA targeting INHBE for obesity, had been completed in its Phase 1 clinical trial. Initial data from this cohort indicated good safety and tolerability, reaching a clinical milestone for the company’s INHBE program. Completion of dosing for the remaining cohorts is expected in 2026. https://finance.eastmoney.com/a/202512153592095373.html
- Source: drugdu
- 121
- December 16, 2025
Juncell Bio plans to list in Hong Kong.

On December 10, Shanghai Junsai Biotechnology Co., Ltd. (hereinafter referred to as “Junsai Biotechnology”) submitted a listing application to the Hong Kong Stock Exchange. According to its prospectus, Junsai Bio is a biotechnology company dedicated to the development of innovative cell therapies and drugs for solid tumors. Its core product, GC101, is expected to become the first approved tumor-infiltrating lymphocyte (TIL) therapy. In 2023, 2024, and the first half of 2025, the company projected net losses of RMB 94 million, RMB 164 million, and RMB 98 million, respectively. The core product GC101 undergoes important testing. According to its prospectus, Junsai Bio focuses on the huge unmet clinical needs in the treatment of solid tumors and is developing the next generation of pan-solid tumor immunotherapy. According to the company, its core product GC101 is currently undergoing a pivotal Phase II clinical trial for the treatment of melanoma, with a Biologics License ...
- Source: drugdu
- 231
- December 15, 2025
Plans to acquire the “Multiple Trace Element Injection Assets” of Tibet Future and its two wholly-owned subsidiaries

On December 14, Zhejiang Zouli Pharmaceutical Co., Ltd. issued an announcement stating that its board of directors had approved the “Proposal on Purchasing an Asset Group and Signing an Acquisition Agreement.” The company plans to acquire a group of trace element injections held by Tibet Future Biomedical Co., Ltd. and its two wholly-owned subsidiaries for a total price (including tax) of RMB 356 million. This asset group covers core assets such as R&D and production technology data, marketing authorizations, trademarks, and patents related to the marketed “Multiple Trace Element Injection (I)” and “Multiple Trace Element Injection (II),” as well as the research and development “Multiple Trace Element Injection (III)” under development. The announcement indicates that multi-trace element injections are a major source of trace elements in parenteral nutrition, especially suitable for nutritional supplementation in special populations such as children and critically ill patients. Among them, multi-trace element injection (I) and ...
- Source: drugdu
- 205
- December 15, 2025
CGE Advances Development of Hexavalent Norovirus Vaccine, Targeting 10-Billion-Yuan Market

News Report – On December 13, the Phase II clinical trial initiation meeting for the hexavalent recombinant norovirus vaccine (a Class 1.1 new drug) independently developed by Vazyme Life Sciences Co., Ltd. (hereinafter referred to as “Vazyme”), a subsidiary of Grand Life Science Group Co., Ltd. (referred to as “Grand Life Science”), was successfully held at the Cenxi City Center for Disease Control and Prevention in Guangxi. According to the reporter, this vaccine is currently the fastest progressing hexavalent norovirus vaccine in global clinical development. It utilizes virus-like particle (VLP) technology and covers six globally prevalent genotypes, theoretically providing coverage for over 90% of circulating norovirus strains worldwide. Norovirus is a leading cause of acute gastroenteritis, characterized by rapid mutation, high infectivity, and fast transmission. The period from October to March each year marks the peak season for norovirus infection in China. At present, there are no specific antiviral drugs ...
- Source: drugdu
- 198
- December 15, 2025
JS212 Clinical Trial Application Approved by US FDA for the Treatment of Advanced Solid Tumors

Junshi Biosciences (688180.SH): JS212 Clinical Trial Application for Advanced Solid Tumors Approved by US FDA BEIJING, December 14 – Junshi Biosciences (688180.SH) announced late evening on December 14 that the company recently received notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for JS212, an EGFR/HER3 bispecific antibody-drug conjugate (ADC), has been approved for the treatment of advanced solid tumors. According to the announcement, JS212 is a recombinant humanized bispecific ADC targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It is primarily intended for the treatment of advanced malignant solid tumors. The company stated that the drug can bind to EGFR or HER3 to exert tumor-inhibiting effects, is expected to be effective against a broader range of tumors such as lung cancer and colorectal cancer, and may potentially overcome drug resistance issues. Preclinical studies showed that ...
- Source: drugdu
- 143
- December 15, 2025
China’s first self-developed, new generation solid tumor drug Zoleretinib approved

InnoCare Announces NMPA Approval of China’s First Self-Developed New Generation TRK Inhibitor, Zoleretinib (ICP-723), for NTRK Fusion-Positive Solid Tumors December 11, 2024 – InnoCare Pharma (stock code: 09969.HK, 688428.SH) announced late evening on December 11 that the National Medical Products Administration (NMPA) has approved its self-developed, new-generation TRK inhibitor, Ichinoclax (Zoleretinib, ICP-723). The drug is indicated for the treatment of adult and adolescent patients aged 12 years and older with locally advanced or metastatic solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. This marks Zoleretinib as the first self-developed new-generation TRK inhibitor in China [1]. NTRK gene fusions are found in a variety of tumor types, having been identified in over 26 different solid tumors to date. In China, an estimated 6,500 new cases of NTRK fusion-positive tumors occur annually. These patients typically face short survival periods, rapid disease progression, and high disability rates. Due to ...
- Source: drugdu
- 286
- December 15, 2025
Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval

Every Cabbage AI Express (NBD AI Express): An investor asked a question on the investor interaction platform: “Hello, Board Secretary. I saw that Chutian Technology mentioned that the vaccine appointment channels opened and immediately sold out. Is this a true reflection of the current influenza vaccine market? If so, why have the stock market performances of the company and its subsidiaries been lukewarm?” Hualan Bio (002007.SZ) replied on the investor interaction platform on December 11th that, according to public data from the National Institutes for Food and Drug Control (NIFDC), the company has obtained lot release approval for 55 batches of influenza vaccines so far this year, ranking among the top domestically in terms of the number of approved batches. Since October, and especially November, public awareness of influenza vaccination has significantly increased. Demand orders from CDCs (Centers for Disease Control and Prevention) across the country have risen significantly compared ...
- Source: drugdu
- 209
- December 12, 2025
Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials

On December 8, Zhaohui Bio-B (02627.HK) announced that the company recently initiated Phase III clinical trials for its lyophilized human rabies vaccine (human diploid cell). The development of this vaccine aims to target three immunization schedules. A new drug clinical trial license was approved by the National Medical Products Administration of the People’s Republic of China (NMPA) in November 2022, followed by the approval of supplementary clinical trial applications for the Zagreb (four-dose) and simplified four-dose regimens in April 2023. The company completed the Phase I clinical trial of this investigational vaccine in October 2024. Rabies is a serious viral disease caused by the rabies virus, and appropriate vaccination can effectively prevent it. Rabies vaccines developed using human diploid cells are recommended by the WHO as the “gold standard” due to their favorable safety characteristics. Although the company demonstrated good safety in the Phase I clinical trials, the announcement also ...
- Source: drugdu
- 159
- December 12, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.